M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Cell Therapeutics Inc reports Complete Response Letter from FDA regarding pixantrone for NHL
Biopharmaceutical company Cell Therapeutics Inc (MTA:CTIC) declared on Friday the receipt of a Complete Response Letter from the US Food and Drug Administration (FDA) for its New Drug Application (NDA) for Pixuvri (pixantrone dimaleate) for relapsed or refractory aggressive non-Hodgkin's lymphoma...If you want to view the full text, you must first purchase archive credits.
Return to Archives
New Search